Avanir Pharmaceuticals (AVNR) Tops Q2 EPS by 2c, Revenue Falls Well Short
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Join SI Premium – FREE
Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q2 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $2.75 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
- Stratasys (SSYS) Tops Q2 EPS by 2c ;; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
